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Objectives: The intracellular antibiotic efficiency of gentamicin-loaded microspheres in the context of
Brucella-infected murine monocytes was examined in vitro with a view to developing improved therapies for
the treatment of brucellosis.
Methods: Biodegradable microspheres made of end-group capped and uncapped poly(lactide-co-
glycolide) 50:50 (PLGA 50:50 and PLGA 50:50H) and containing gentamicin sulphate were used to target
Brucella abortus-infected J774 monocyte-macrophages. The infected cells were treated with 15 µg of free or
microencapsulated gentamicin and the efficacy of the treatments was measured after 24 h.
Results: The particle sizes were below 8 µm and in vitro release of gentamicin from the microspheres
followed a continuous (PLGA 50:50H) or a multiphasic (PLGA 50:50) pattern over 50 days. Treatment with
gentamicin microencapsulated into the end-group uncapped PLGA 50:50H microspheres, decreased
significantly the number of intracellular bacteria (typically by 2 log10) in comparison with untreated infected
cells. Addition of 2% poloxamer 188 to the microsphere dispersion medium further reduced the infection
(3.5 log10). Opsonization of the particles with non-immune mouse serum had no effect on the antibacterial
efficacy of the microspheres. End-group capped PLGA 50:50 type microspheres containing the antibiotic
were less effective at reducing intracellular bacteria (∼1 log10 reduction), although addition of poloxamer 188
to the dispersion medium again enhanced their intracellular antibacterial activity. Placebo PLGA 50:50 and
PLGA 50:50H microspheres had no bactericidal activity.
Conclusions: The results indicate that PLGA 50:50-microencapsulated gentamicin sulphate may be suitable
for efficient drug targeting and delivery to reduce intracellular Brucella infections.
Keywords: biodegradable microspheres, drug delivery systems, Brucella-infected monocytes
Introduction
Brucellosis is an infectious disease caused by Brucella spp. Four
species, Brucella abortus, Brucella melitensis, Brucella suis and
Brucella canis, have been recognized as human pathogens each
associated with a different natural host animal. These small cocco-
bacilli are mainly localized intracellularly within phagocytic cells
making treatment difficult, since most antibiotics, although highly
active in vitro, do not actively pass through cellular membranes.1
Treatment for brucellosis remains controversial and requires pro-
longed therapy with at least two agents. The choice of regimen and
duration of therapy is based on the presence of focal disease, under-
lying patient conditions and age group which may contraindicate
certain antibiotics. Attempts at monotherapy with trimethoprim/
sulfamethoxazole, macrolides or fluoroquinolones have met with
disappointing relapse rates despite excellent in vitro activity.2 A
prolonged administration of a tetracycline–aminoglycoside combin-
ation (i.e. doxycycline 100 mg twice/day for 45 days, and strepto-
mycin 1 g/day for 14 days or gentamicin 5–6 mg/kg per day for
7 days) has lower relapse rates than the more usual doxycycline–
rifampicin combination recommended by the World Health Organi-
zation in uncomplicated cases.2 An extended doxycycline–
aminoglycoside regimen is also the preferred therapeutic option in
life-threatening forms of the disease, such as endocarditis.2 However,
3–5% relapse rates, serious side effects (especially in children and
pregnant women), and hampered patient compliance, mainly caused
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by the long-term treatment and the inconvenience of parenteral
administration of aminoglycosides, still represent major hurdles
contributing to low therapeutic efficacy.2
Gentamicin sulphate is an aminoglycoside with a wide spectrum
of antibacterial activity though important side effects mostly related
to nephrotoxicity and ototoxicity restrict its use.3 It is a highly soluble
drug but does not cross cell membranes efficiently, which is an
important drawback for the therapy of intracellular infections such as
brucellosis, due to the low antibiotic levels achievable inside infected
cells. Several reports indicate that gentamicin is more active in vitro
against clinical isolates of Brucella than streptomycin.4 In combined
doxycycline–aminoglycoside regimens, gentamicin appears to be
more cost-effective and less toxic given the duration of the adminis-
tration (14–21 days for streptomycin compared with 7 days for genta-
micin), with no increases in clinical relapse or treatment failure.2
These properties make gentamicin an attractive candidate for the
treatment of brucellosis provided that the antibiotic can be delivered
intracellularly. Therefore, an optimum strategy to treat brucellosis
should target a highly active drug to the intracellular compartment
and prolong the release of that antibiotic, thereby reducing the
number of doses to be administered and minimizing drug side effects.
Liposomes containing gentamicin are quite efficient for targeting
Brucella-infected monocyte-macrophages.5 Liposomes have a
membrane-like structure that favours a good cell interaction and their
versatility in terms of structure and composition grant their main
advantages. However, liposomes suffer from low encapsulation
efficiency, stability problems, both during storage and upon injec-
tion, their therapeutic efficacy is not always optimal and cannot
provide a controlled release of the encapsulated drug.6 Small bio-
degradable microspheres are attractive alternatives to liposomes for
targeting drug in the monocyte-macrophagic system. Upon phago-
cytosis of antibiotic-loaded microspheres, intracellularly located and
highly protected bacteria, such as Mycobacterium tuberculosis, Sal-
monella typhimurium, Listeria monocytogenes and Brucella spp.,
may become accessible to antibiotic treatment. Biodegradable
microspheres made of poly(lactide) (PLA) and its copolymers with
glycolide (PLGA) can release encapsulated drugs in a sustained
manner, depending on the physicochemical properties of the polymer
and drug, and the microencapsulation procedure.7 Microsphere tech-
nology has been widely used for a wide variety of therapeutic
compounds including antibacterial agents.8–11 Thus, PLA/PLGA
microspheres should be a potentially suitable and stable delivery
system for antibiotic treatment of brucellosis that could provide con-
trolled release of the encapsulated drug and minimize the need for
multiple injections.
In this study, we examined the intracellular antibiotic efficiency of
gentamicin-loaded microspheres in the context of Brucella-infected
murine monocytes. Two microsphere types, made of end-group
capped PLGA 50:50 and uncapped PLGA 50:50H, were used
because they are phagocytosed efficiently by monocytes in vitro;12
the end-group uncapped PLGA 50:50H microspheres also promote
cell activation, as measured by oxidative burst.12,13
Materials and methods
Preparation of microspheres loaded with gentamicin
Gentamicin was microencapsulated by spray-drying into poly(D,L-
lactide-co-glycolide) carrying either capped, i.e. esterified end-groups,
or uncapped, i.e. free hydroxyl and carboxyl end-groups,14 hereafter
abbreviated as PLGA 50:50 and PLGA 50:50H, respectively. Briefly,
100 mg of gentamicin was dissolved in 1 mL of PBS (67 mM, pH 7.4 or
6.0), which was then dispersed in 20 g of a 5% (w/w) polymer solution in
ethyl formate by ultrasonication under cooling on ice. The water-in-oil
emulsion formed was spray-dried (Mini Spray Drier B-190; Büchi,
Flawil, Switzerland) and the resulting microspheres were collected on a
cellulose acetate filter of 0.8 µm pore size. Microspheres were washed
with 0.1% (w/w) poloxamer 188 solution, rinsed with distilled water and
dried under vacuum (∼10 mbar). Residual water was eliminated by dis-
persing the particles in n-hexane, followed by additional vacuum drying
for 24 h. The final product was stored under dry conditions at 4°C.
Placebo microspheres were produced accordingly, but without the genta-
micin solution.
Determination of microsphere size and morphology
Microsphere size distribution was determined by laser light scattering
(Mastersizer X; Malvern Instruments, Malvern, UK). The morphology
of the microspheres was examined in a Zeiss DSM 940A scanning elec-
tron microscope.
Gentamicin content in the microspheres
Gentamicin content in the microspheres was determined by dissolving
40 mg of particles in 3 mL of dichloromethane and collecting the undis-
solved gentamicin on regenerated cellulose filters of 0.2 µm pore size.
The dried filters were transferred into test tubes and the antibiotic was
eluted with 2 mL of water and assayed photometrically (320–350 nm)
after derivation with o-phthalaldehyde.14 Gentamicin extraction from the
microspheres was carried out in triplicate and the eluted gentamicin was
determined from the replicates.
In vitro release of gentamicin from microspheres
Gentamicin release was determined by suspending ∼10–30 mg of micro-
spheres, weighed accurately, in 4 mL of PBS (67 mM, pH 7.4) containing
0.05% polysorbate 20 and 0.02% sodium azide, in borosilicate vials
(Chromacol, Welwyn Garden City, UK). The vials were briefly soni-
cated to facilitate wetting of the particles and placed horizontally on a
shaking platform at 37°C. At regular intervals, the vials were centrifuged
at 2000g for 10 min to obtain a particle-free supernatant that was assayed
fluorometrically with a Cytofluor 2300/2350 (Millipore)5 after deriva-
tion of the gentamicin with o-phthalaldehyde. At every sampling point,
the release medium collected was replaced with fresh phosphate buffer.
Burst release was described as the amount of drug released after 24 h.
Gentamicin release from the microspheres was determined in triplicate
for each microsphere preparation.
J774 murine monocyte-macrophage cell line
The J774.2 murine monocyte-macrophage cell line was obtained from
the European Collection of Cell Cultures (ECACC No. 85011428). The
cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 2 mM L-glutamine, 10% (v/v) heat-inactivated fetal
calf serum and preserved with 0.1% antibiotic-antimycotic solution
(complete medium) at 37°C, 5% CO2 and controlled humidity.
Brucella strain and preparation of bacteria for infection
B. melitensis is the more frequent cause of Brucella human infections.
However, as it is a class three pathogen, B. abortus was chosen for these
studies. B. abortus 2308 was isolated from spleens of infected mice by
homogenization of the organ in saline solution (Stomacher 80 Lab
Blender; Seward Medical, London, UK) and seeding onto trypticase soy
agar (TSA) plates (bioMérieux, France). Further, the bacterial colonies
were suspended on skimmed milk and maintained in cryovials at –85°C.
Microspheres to treat Brucella-infected monocytes
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For monocyte infection, the brucellae were thawed, seeded onto TSA
plates and incubated for 2–3 days at 37°C. Two or three isolated colonies
were transferred into 5 mL of trypticase soy broth (TSB) and incubated
for 20–24 h at 37°C under shaking, so that the bacteria reached exponen-
tial growth phase. The bacterial suspension was first diluted in TSB to an
optical density of 0.12 (590 nm) and further diluted in saline solution to a
concentration of ∼5×107 cfu/mL to infect the cultured monocytes.
Infection of monocytes with Brucella abortus 2308
J774 murine monocytes cultured in complete medium were washed,
collected by centrifugation and cell viability was determined by Trypan
Blue exclusion. Cell numbers were adjusted to 2 × 106 cells/mL and
500 µL of the cell suspension was added to each well of a 24-well culture
plate (Nunc, Naperville, IL, USA). The cells were incubated in DMEM
supplemented with L-glutamine and 10% (v/v) fetal calf serum for 2–3 h
to allow cell adherence. Afterwards, the medium was withdrawn to
remove non-adherent cells and replaced. For bacterium-specific opsoniza-
tion, the B. abortus suspension, previously adjusted to an adequate
bacterial concentration as described above, was shaken with a sub-
agglutinating concentration of antiserum from B. abortus-infected mice
for 30 min at 37°C. Then, 100 µL of opsonized B. abortus was added to
the monocytes at a ratio of 5 bacteria per cell and further incubated at
37°C for 1–48 h. After incubation, the culture medium was discarded, the
infected cells were carefully washed five times to remove extracellular
bacteria and 500 µL of DMEM was added to each well. The number of
remaining extracellular bacteria in each well was determined by diluting
and seeding the added medium onto TSA plates. The total number of cfu
per well was determined after lysing the monocytes with cold 0.2%
Triton X-100 for 20 min at 37°C, thorough homogenization and plating
of serial dilutions of the lysates onto TSA plates. This Triton X-100 treat-
ment had no effect on viability of the bacteria. Intracellular bacteria were
calculated by subtracting the number of extracellular Brucella from the
total cfu counts in three wells.
Treatment of Brucella-infected monocytes with 
gentamicin-loaded microspheres
The infected J774 monocytes were treated with 15 µg of free gentamicin
sulphate in solution, with placebo microspheres, or with gentamicin-
loaded microspheres containing 15 µg of the antibiotic, and the effective-
ness of the different treatments in reducing the number of intracellular
bacteria was determined. The influences of prior opsonization of the par-
ticles in fresh mouse serum and the presence of 2% (w/v) of the non-ionic
surfactant poloxamer 188 in the microsphere dispersion medium were
also determined. For opsonization, the microspheres were dispersed in
DMEM supplemented with L-glutamine and containing 8% (v/v) non-
immune fresh mouse serum and incubated at 37°C under shaking for
30 min. In some experiments, the microspheres were simply dispersed in
the 8% (v/v) serum solution without incubation.
The J774 monocytes-macrophages were infected by incubating the
cells with the opsonized B. abortus for 15 h at a bacteria/cell ratio of 5:1 as
described above. Afterwards, non-phagocytosed bacteria were removed
by washing carefully five times and the effectiveness of the different
treatments was studied by incubating the infected monocytes for 24 h at
37°C and 5% CO2 with 1 mL of DMEM/L-glutamine containing either
free gentamicin in solution, gentamicin encapsulated in microspheres or
placebo microspheres. DMEM/L-glutamine without fetal calf serum was
used to avoid potential effects of the serum proteins on the particle uptake
and to moderate the proliferation of monocytes and bacteria. Further,
cells were washed twice with DMEM/L-glutamine and extracellular cfu
and total cfu after cell lysis with Triton X-100 were determined by plating
serial dilutions onto TSA plates as described previously. Intracellular
brucellae were calculated by subtracting the number of extracellular bac-
teria from the total cfu counts in three wells. Results were expressed as
log10 of intracellular Brucella surviving the treatments and the efficiency
of the treatments was tested in one to six independent assays.
In vitro susceptibility of B. abortus to gentamicin and 
poloxamer
Gentamicin sulphate and poloxamer 188 as single agents or in combin-
ation were tested for their ability to inhibit the bacterial growth of B.
abortus in broth culture. Gentamicin sulphate was added to the bacterial
suspension to obtain final concentrations of 0.007–0.960 µg/mL, alone
or in combination with 0.5, 1 and 2% (w/v) poloxamer 188. Bacterial
growth in TSB was measured turbidimetrically with an automated
Labsystems Bioscreen (Finland) using Bioscreen microtitre plates
(100-well honeycomb). Organisms were retrieved from suspensions
stored at –85°C in cryoballs (Microbank, Biolab Diagnostics, Canada),
plated on TSA and incubated at 37°C overnight. Several colonies were
then subcultured in TSB at 37°C for 36 h to reach mid-log phase. The
final inoculum suspension was prepared in TSB and adjusted to an
optical density of 0.12 (590 nm) (∼108 cfu/mL). The real inoculum dose
was estimated by plating appropriate dilutions of the stock suspension
onto TSA plates. Finally, an inoculum of 105 cfu per well was added into
Bioscreen plates containing serial dilutions of the agents (gentamicin
and/or poloxamer 188). Appropriate positive and negative growth
controls were also included. The optical density of each well was
measured automatically at 30 min intervals using wide band irradiation
(420–580 nm) and bacterial growth curves were generated.
Statistical analysis
Comparisons were made between groups by a one-way analysis of vari-
ance (ANOVA) and post-hoc Tukey’s HSD test. The statistical signifi-
cance level was defined as P < 0.05.
Results
Microsphere size, gentamicin loading and in vitro release
The average diameter of the PLGA 50:50H and PLGA 50:50 micro-
spheres was ∼4 µm, except for the placebo PLGA 50:50 micro-
spheres which had an average diameter of 0.5 µm (Table 1). This size
appeared adequate for cellular uptake and was mainly a result of the
encapsulation method used. Scanning electron micrographs showed
spherically shaped and regular particles with smooth surfaces for
both the placebo and gentamicin-loaded PLGA 50:50 microspheres.
Gentamicin-loaded PLGA 50:50H microspheres were, however,
porous and the particles tended to aggregate.
The actual gentamicin loading was 22 and 15 µg/mg microspheres
and the in vitro gentamicin burst release amounted to 7.8 and 2.0 µg
for the PLGA 50:50 and PLGA 50:50H, respectively (Table 1). Addi-
tional gentamicin release from PLGA 50:50H microspheres occurred
in a continuous fashion and from PLGA 50:50 microspheres in a
multiphase-like pattern (Figure 1).
Kinetics of Brucella uptake and replication in cultured J774 
monocytes
Opsonized B. abortus were incubated from 1 to 48 h with J774 cells in
complete medium without antibiotic-antimycotic supplement and
afterwards, the number of extracellular and intracellular bacteria was
determined. Incubation for 1 h was insufficient for significant phago-
cytosis of opsonized bacteria at a monocyte/Brucella ratio of 1:5.
Incubation times between 15 and 48 h allowed an adequate number of
S. Prior et al.
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intracellular brucellae to carry out our study (Figure 2). In this time,
the bacteria reached the intracellular compartment and multiplied
within the monocytes increasing by approx 1.3 log10 after 48 h. Incu-
bation times above 48 h resulted in excessive cell and bacteria pro-
liferation, as reflected by turbidity and diminished cell viability.
Therefore, for all antibiotic activity assays, an infection time of 15 h
was chosen. Thus, the cells were incubated with the bacteria for 15 h,
non-phagocytosed bacteria were washed off and the different treat-
ments were subsequently applied. Under these conditions, the per-
centage of intra- and extracellular Brucella at the time of the
antibiotic treatments was 93–95% and 5–7%, respectively.
Efficacy of gentamicin-loaded microspheres in reducing 
intracellular Brucella from infected monocytes: effect of 
polymer type
Monocytes infected with Brucella were treated for 24 h with (i) free
gentamicin in solution, (ii) gentamicin encapsulated in PLGA 50:50
or PLGA 50:50H microspheres, and (iii) placebo PLGA 50:50 or
PLGA 50:50H microspheres. The amounts of microspheres used per
well were 0.7 mg for PLGA 50:50 and 1.0 mg for PLGA 50:50H,
which corresponded to a gentamicin dose of 15 µg/well for both
Table 1. Characteristics of the gentamicin (GEN)-loaded microsphere (MS) batches used in this study for the in 
vitro treatment of murine J774 monocytes-macrophages infected with Brucella abortus 2308
aGEN, loaded with gentamicin. The commercial products of PLGA 50:50 and PLGA 50:50H were Resomer RG502 and
RG502H, respectively.
b50% and 90%-undersize diameters.
cNominal loading was 100 µg gentamicin/mg microspheres. Actual loading is expressed as µg of gentamicin per mg of micro-
spheres and represents the mean value ± S.D. of three replicates.
dGentamicin in vitro burst release from the microspheres after 24 h incubation in phosphate buffer (67 mM, pH 7.4, 0.05%
Tween 20, preserved with 0.02% sodium azide). The values represent the mean value ± S.D. of three replicates.
ePercentage of the total gentamicin content in the microspheres.
fThe gentamicin dose used for in vitro treatment of infected monocytes was 15 µg, corresponding to 0.7 mg of PLGA 50:50 and
1 mg of PLGA 50:50H microspheres. The values indicate the absolute amount of gentamicin released in vitro within 24 h from
the applied quantities of microspheres.
Number weighted 
microsphere diameters 
(µm)b In vitro burst released
Microsphere formulationa d50%            d90%
Actual loadingc 
(µg GEN/mg MS)       (%)e (µg GEN/dose MSf)
GEN-PLGA 50:50 3.8 7.6 22.4 ± 1.6 50.0 ± 4.1 7.8 ± 0.6
Placebo PLGA 50:50 0.5 0.8 – – –
GEN-PLGA 50:50H 3.9 7.7 14.8 ± 0.6 13.5 ± 0.9 2.0 ± 0.1
Placebo PLGA 50:50H 3.5 6.8 – – –
Figure 1.
 In vitro gentamicin release from PLGA 50:50 (filled circles) and PLGA
50:50H (filled triangles) microspheres. Results are expressed as percentage of
cumulative gentamicin release and represent the mean value ± S.D. of three repli-
cates.
Figure 2.
 Brucella abortus phagocytosis and intracellular growth kinetics in
murine J774 monocyte-macrophages. Cells were infected at a cell to bacteria
ratio of 1:5 (filled symbols) and incubated for 1–48 h. The number of intracellular
brucellae at different time points is shown (open symbols). Results are expressed
as log10 of cfu and represent the mean value ± S.D. of three wells.
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microsphere types; corresponding amounts of placebo microspheres
were used. A dose of 15 µg of gentamicin was used to ensure the
intracellular delivery of the antibiotic at levels well above the MBC
(0.06 mg/L, see below). Placebo microspheres had no bactericidal
effect on intracellular Brucella counts. In contrast, treatment with
gentamicin-loaded microspheres reduced intracellular bacteria,
compared with untreated controls, by 1.0 and 2.0 log10 for PLGA
50:50 and PLGA 50:50H, respectively. Free gentamicin in solution
exerted variable intracellular bactericidal activity in different experi-
ments, varying from a 1.1 to 1.8 log10 reduction. However, treatment
with gentamicin-loaded PLGA 50:50H microspheres was signifi-
cantly more effective at reducing the intracellular infection than free
gentamicin treatment (Figure 3).
Efficacy of gentamicin-loaded microspheres in reducing 
intracellular Brucella from infected monocytes: effect of 
particle opsonization and addition of poloxamer 188 to the 
culture medium
Previous results in our laboratory showed that opsonization of
gentamicin-loaded microspheres increased significantly the capacity
of the particles to induce oxidative burst of monocytes,12 which may
potentially increase the bactericidal activity of antibiotic treatments.
With that hypothesis, the effect of opsonization on the antibacterial
efficacy of the microsphere treatment was examined in this study.
Our hypothesis was, however, not supported by our findings. The
antibiotic activity of the gentamicin-loaded microspheres did not
increase upon particle opsonization (Figure 3). In contrast, addition
of 2% (w/v) of poloxamer 188 to the medium to improve the dis-
persion characteristics of the microspheres, enhanced significantly
the intracellular antibiotic activity of the gentamicin-loaded PLGA
50:50H microspheres (Figure 4). In the presence of the surfactant, the
total reduction of intracellular bacteria reached 3.5 log10 cfu, relative
to the untreated monocytes, which represented a 1.2 log10 further
reduction in intracellular cfu relative to the same treatment without
poloxamer 188. A similar improvement, i.e. ∼1 log10 further reduc-
tion, was also observed with the gentamicin loaded end-group
capped PLGA 50:50 microspheres when the poloxamer was added to
the medium; however, in this case the increase was not statistically
significant. Control wells demonstrated the lack of activity of both a
poloxamer 188 solution and a suspension of placebo microspheres in
poloxamer on the viability of the intracellular Brucella.
In vitro susceptibility of Brucella abortus to gentamicin and 
poloxamer
The effect of combining gentamicin sulphate and poloxamer 188
against B. abortus was studied in broth culture in vitro. When sub-
MIC concentrations of gentamicin sulphate and non-inhibitory con-
centrations of poloxamer 188 were combined, a synergic effect was
evidenced between the two agents (not shown). For example, the
Figure 3. Efficacy of free gentamicin, gentamicin-loaded and unloaded PLGA 50:50 and PLGA 50:50H microspheres in reducing intracellular Brucella infection in
J774 monocytes in vitro. The effect of opsonization with 8% (v/v) fresh mouse serum is also shown (shaded bars). Bars represent the average ± standard error of the
means of up to six independent assays; * and # symbols indicate significant differences (P < 0.05) in the Tukey test.
Figure 4. Effect of adding 2% (w/v) poloxamer 188 to the incubation medium
(filled bars) on the intracellular bactericidal activity of gentamicin-loaded PLGA
50:50 and PLGA 50:50H microspheres. The effect in medium alone is shown
with open bars. Bars represent the average ± standard error of the means of up to
six independent experiments; * and # symbols indicate significant differences
(P < 0.05) in the Tukey test.
S. Prior et al.
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MBCs (3 log10 reduction) of gentamicin and poloxamer 188 tested
alone were 0.06 mg/L and >2% (w/v), respectively. When genta-
micin was combined with the poloxamer at 1% or 2% (w/v), the
MBC of gentamicin was reduced to 0.03 mg/L (poloxamer 1%) and
0.015 mg/L (poloxamer 2%).
Discussion
Our previous studies showed that gentamicin-containing PLA and
PLGA microspheres are efficiently phagocytosed and that end-group
uncapped PLGA 50:50H microspheres stimulated highly the oxi-
dative burst of monocyte-macrophages.12 In this work, we hypothe-
sized that intracellular oxygen radicals produced upon microsphere
internalization might act synergically with the antibiotic in killing
intracellular bacteria.
Gentamicin-loaded PLGA 50:50H microspheres decreased
significantly the intracellular bacterial levels (typically by 2 log10)
compared with untreated monocytes and free gentamicin; the effi-
ciency of PLGA 50:50 microspheres was lower (typically 1 log10
reduction) and normally no different to the free drug; placebo micro-
spheres had no effect. Opsonization of gentamicin-loaded micro-
spheres in fresh mouse serum did not improve the antibiotic efficiency
of the treatment although, in previous work, opsonization increased
the uptake of placebo microspheres and the cell oxidative meta-
bolism.12 The release of oxygen metabolites can alter the bacterial
membrane permeability and thereby increase drug efficiency.15
Because Brucella spp. alone only slightly increase the oxidative burst
in blood leucocytes, we speculated that an enhanced production of
oxidative metabolites triggered by the phagocytosis of microspheres
should improve treatment efficacy. This hypothesis was supported
by the observation that brucellicidal activity of human polymorpho-
nuclear leucocyte granule lysates was enhanced by addition of hydro-
gen peroxide.16 In our experiments, no bactericidal effect was
observed with placebo PLGA 50:50H microspheres. Nevertheless,
the stimulation of oxygen derivatives within the cells may have
increased the bacterial membrane permeability and made them more
susceptible to the antibiotic.
Free gentamicin sulphate lowered the number of intracellular
bacteria by ∼1 to 1.8 log10. Because gentamicin cannot diffuse
through cellular membranes, its internalization and accumulation
inside cells has been ascribed to pinocytosis.17 The observed varia-
tion in the reduction in bacterial counts might result from variations
in the pinocytic capacity of the cells. In our investigation, micro-
encapsulated gentamicin achieved bacterial reduction at levels
superior or comparable to free drug. Considering that gentamicin
release from the microspheres was prolonged over up to 50 days,
antibiotic activity may be expected for prolonged periods of time.
Incubation times were not prolonged in our studies due to limited cell
viability and high bacterial proliferation. We hypothesize that this
may provide intracellular bactericidal gentamicin concentrations
over prolonged periods of time. Thus, this approach could reduce the
multiple injections needed in the aminoglycoside component of
current brucellosis therapies, and could ensure efficient clearance
of the infection without increasing the possibility of ototoxic and
nephrotoxic reactions. It would therefore be interesting to quantify
the intracellular concentration of gentamicin after microsphere
uptake to improve understanding of the mechanism and kinetics by
which the encapsulated drug reduces intracellular Brucella. None-
theless, in vivo processing of the microspheres is likely to affect the
kinetics of drug release and polymer degradation. Intracellular reduc-
tion of Brucella was greater for PLGA 50:50H than for PLGA 50:50
microspheres, although in vitro burst release within the initial 24 h of
incubation amounted to only 14% for the PLGA 50:50H as compared
with 50% for the PLGA 50:50 microspheres. Two factors may
explain the results. First, the pronounced stimulation of oxidative
metabolites by the PLGA 50:50H particles may have enhanced the
antibiotic activity of gentamicin. Second, a higher number of PLGA
50:50H particles might have been phagocytosed, because a larger
amount of these particles had been added to the infected monocytes to
achieve identical gentamicin doses (1 mg of PLGA 50:50H versus
0.7 mg of PLGA 50:50 microspheres, with both types having a similar
phagocytosis rate of ∼50%).12 However, the present data are insuffi-
cient to conclude that a higher number of phagocytosed particles
directly affect antimicrobial efficacy.
An interesting result of this study was the increased antibacterial
activity (up to 1.2 log10) of microencapsulated gentamicin when
the dispersion medium for the microspheres contained 2% (w/v)
poloxamer 188. Several mechanisms may be responsible for this
phenomenon: (i) adsorption of the surfactant on the microsphere
surface thereby altering the surface polarity and the potential for cell
adhesion; (ii) enhanced phagocytosis due to a higher degree of par-
ticle dispersion or another mechanism; (iii) non-specific cell activa-
tion by the surfactant; and (iv) synergic enhancement of antibiotic
activity. Particle coating by poloxamer type surfactants is well
known to suppress phagocytosis in vitro and alter the opsonization by
serum proteins in vivo, slowing down the elimination of particles
from the blood by the mononuclear phagocytic system.18 The effi-
ciency of poloxamer types to reduce particle phagocytosis depends
on the molecular weight and chain length of the propylene oxide (PO)
and ethylene oxide (EO) blocks.18 Thin coatings conferring poor
steric stabilization were obtained on highly polar surfaces19,20 where
the PO blocks were adsorbed preferentially onto the particle surface,
whereas the EO chains stretched out into the dispersion medium.18
On larger particles, such a thin layer was probably adsorbed flatly so
that the hydrophobic PO units remained exposed to the medium.
With the relatively polar and hydrophilic PLGA 50:50 and PLGA
50:50H microspheres studied herein, adsorption of poloxamer prob-
ably occurred through interaction with the EO chains, resulting in a
flat arrangement of adsorbed poloxamer. As a result, the exposed PO
chains possibly increased the hydrophobicity of the particle surface,
leading to increased particle uptake by monocytes, as observed by
optical microscopy (data not shown). Further, improved particle dis-
persion in 2% poloxamer 188 should have also contributed to the
increased phagocytosis. Finally, mechanisms involving interaction
between poloxamer and cell membrane21,22 or cell activation cannot
be excluded. Some poloxamers have indeed increased phagocytic
activity, and altered bacterial cell wall integrity and permeability
yielding a synergic effect with antibiotic agents.23–26 Our suscep-
tibility studies in culture broth demonstrated that poloxamer can
potentiate the antibacterial activity of gentamicin. Enhancement of
antibiotic susceptibility was observed with subinhibitory concentra-
tions of poloxamer. However, no bactericidal effect of 2% soluble
poloxamer alone or 2% poloxamer incubated with placebo micro-
spheres was observed on the intracellular bacterial counts. The results
indicate that only non-inhibitory amounts of poloxamer may reach
the intracellular bacteria. Nevertheless, non-inhibitory concentra-
tions of the surfactant may have synergically enhanced the anti-
Brucella activity of gentamicin delivered intracellularly from micro-
spheres by as yet unknown mechanisms.
Finally, an important aspect for discussing the effectiveness of
encapsulated gentamicin is the location of the Brucella inside the
cell. Intracellular bacteria can evade the host defences by different
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mechanisms and prevention of phagosome–lysosome fusion has
been proposed for intracellular survival of virulent Brucella spp., e.g.
B. abortus 2308.27 B. abortus is located in the perinuclear region
within compartments resembling autophagosomes and is then deliv-
ered to the endoplasmic reticulum where intracellular bacterial repli-
cation takes place.28–30 This special localization of B. abortus might
prevent contact between bacteria and antibiotic-loaded micro-
spheres. On the other hand, virulent Brucella can transit from early
endosomes to autophagosomes, which apparently did not fuse with
endosomes loaded with exogenous material.30 Nonetheless, fusion
between phagosomes and other endocytic vesicles can generally
occur, so that phagosomes loaded with particles or pinocytic endo-
somes have the potential to eliminate Brucella that reside in access-
ible phagosomes.17 Two localizations for B. abortus have been found
at 24 h post-infection: accessible single membrane phagosomes and
multimembranous autophagosomes,28 where the bacteria may escape
from the antibiotics delivered to phagosomes.
In conclusion, we suggest that microsphere internalization is
responsible for the significant reduction in the intracellular bacteria
by gentamicin-loaded PLGA 50:50 and PLGA 50:50H microspheres
within 24 h. Microencapsulated gentamicin was efficiently targeted
to infected monocytes and reduced intracellular Brucella infections.
In addition, gentamicin may still be available for further release from
the microspheres for prolonged periods of time. Poloxamer 188
added to the dispersion medium for the microspheres significantly
enhanced the efficiency of the antibiotic treatment. Further studies
should focus on determining the mechanisms by which microencap-
sulated gentamicin is capable of reducing intracellular viable Bru-
cella and investigate the efficacy of gentamicin-loaded microspheres
in the treatment of brucellosis in vivo.
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